<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>KISS1 is a <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> suppressor lost in several solid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We evaluated the clinical relevance of KiSS-1 methylation and its protein expression in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The epigenetic silencing of KiSS-1 by hypermethylation was tested in <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cells (n = 5) before and after azacytidine treatment </plain></SENT>
<SENT sid="3" pm="."><plain>KiSS-1 methylation was evaluated by methylation-specific PCR in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells, and <z:mpath ids='MPATH_458'>normal</z:mpath>, benign, and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissues (n = 352) were grouped in a training set (n = 62) and two independent validation cohorts (n = 100 and n = 190) </plain></SENT>
<SENT sid="4" pm="."><plain>KiSS-1 protein expression was analyzed by immunohistochemistry on tissue arrays </plain></SENT>
<SENT sid="5" pm="."><plain>KiSS-1 hypermethylation correlated with transcript and protein expression loss, being increased in vitro by azacytidine </plain></SENT>
<SENT sid="6" pm="."><plain>Methylation rates were 53.1, 70.0, and 80.0 % in the training and validation sets, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>In the training set, KiSS-1 methylation rendered a diagnostic accuracy of 72.7 % (p = 0.002) </plain></SENT>
<SENT sid="8" pm="."><plain>Combination of KiSS-1 methylation and serum CEA (p = 0.001) increased the prognostic utility of CEA alone (p = 0.022) </plain></SENT>
<SENT sid="9" pm="."><plain>In the first validation set, KiSS-1 methylation correlated with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> grade (p = 0.011), predicted recurrence (p = 0.009), <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> (p = 0.004), disease-free (p = 0.034), and overall survival (p = 0.015) </plain></SENT>
<SENT sid="10" pm="."><plain>In the second validation cohort, KiSS-1 methylation predicted disease-specific survival (p = 0.030) </plain></SENT>
<SENT sid="11" pm="."><plain>In the training set, cytoplasmic KiSS-1 expression was significantly higher in nonneoplastic biopsies as compared to <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> (p &lt; 0.0005) </plain></SENT>
<SENT sid="12" pm="."><plain>In the validation set, loss of cytoplasmic expression correlated with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> stage (p = 0.007), grade (p = 0.035), recurrence (p = 0.017), and disease-specific survival (p = 0.022) </plain></SENT>
<SENT sid="13" pm="."><plain>KiSS-1 was revealed epigenetically modified in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="14" pm="."><plain>The diagnostic and prognostic utility of KiSS-1 methylation and expression patterns suggests their assessment for the clinical management of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients </plain></SENT>
</text></document>